Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
California Cancer Consortium
With
OBJECTIVES: Primary * Determine the 6-month progression-free survival of patients with unresectable or metastatic renal cell carcinoma treated with gefitinib and PEG-interferon alfa-2b. Secondary * Determine the response rate (by RECIST criteria), duration of response, time to treatment failure, and overall survival of patients treated with this regimen. * Assess toxicity and tolerability of this regimen in these patients. * Determine the pre-treatment expression of the von Hippel-Lindau (VHL) protein, the epidermal growth factor receptor (EGFR), and p27, and correlate with response to treatment. * Determine post-treatment alteration of EGFR and p27 expression in patients with tumors accessible for serial biopsy. * Assess changes in EGFR levels in buccal epithelial cells in patients treated with this regimen. OUTLINE: This is a multicenter study. Patients receive oral gefitinib once daily and PEG-interferon alfa-2b subcutaneously once weekly in weeks 1-6. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with a partial response or stable disease after completion of course 2 continue to receive gefitinib alone as above in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed periodically for up to 2 years. PROJECTED ACCRUAL: A total of 39 patients will be accrued for this study.
Age
18–120
Sex
ALL
Healthy volunteers
Not accepted
